REGULATORY

1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition

June 15, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

First generic versions for 13 APIs (252 products) including those for major brands Micardis (telmisartan) and Abilify (aripiprazole) will be added to the NHI reimbursement price list on June 16, the Ministry of Health, Labor and Welfare (MHLW) announced in…

To read the full story

Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
Talion AG, 2 Other APIs Skip December Gx Listing
December 8, 2016

REGULATORY

PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…